483pchange in Plasma Protein Binding of Sn-38, an Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure (srf).
نویسندگان
چکیده
K. Fujita1, H. Okumura2, Y. Masuo2, Y. Sunakawa3, K. Shimada4, K. Kawara5, Y. Akiyama5, Y. Sasaki6, Y. Kato2 Inst Molecular Oncology, Showa University, Tokyo, JAPAN Faculty of Pharmacy, Kanazawa University, Kanazawa, JAPAN Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, JAPAN Internal Medicine, Showa University Koto Toyosu Hospital, Tokyo, JAPAN Medical Oncology, Saitama Medical University, Hidaka, JAPAN Internal Medicine, Showa University, Tokyo, JAPAN
منابع مشابه
Short Communication Delayed Elimination of SN-38 in Cancer Patients with Severe Renal Failure
This prospective study is designed to examine the effects of severe renal failure on the pharmacokinetics of irinotecan. The pharmacokinetics of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), and SN-38 glucuronide (SN-38G) in three cancer patients with severe renal failure [creatinine clearance (Ccr) <20 ml/min] who were undergoing dialysis and received 100 mg/m irinotecan as monotherapy w...
متن کاملShort Communication Delayed Elimination of SN-38 in Cancer Patients with Severe Renal Failure
This prospective study is designed to examine the effects of severe renal failure on the pharmacokinetics of irinotecan. The pharmacokinetics of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), and SN-38 glucuronide (SN-38G) in three cancer patients with severe renal failure [creatinine clearance (Ccr) <20 ml/min] who were undergoing dialysis and received 100 mg/m irinotecan as monotherapy w...
متن کاملShort Communication Delayed Elimination of SN-38 in Cancer Patients with Severe Renal Failure
This prospective study is designed to examine the effects of severe renal failure on the pharmacokinetics of irinotecan. The pharmacokinetics of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), and SN-38 glucuronide (SN-38G) in three cancer patients with severe renal failure [creatinine clearance (Ccr) <20 ml/min] who were undergoing dialysis and received 100 mg/m irinotecan as monotherapy w...
متن کاملActa Medica 4/12 2802.indd
The colorectal cancer ranks high among the malignant tumours in incidence and mortality and irinotecan is standardly used in palliative treatment of metastatic disease in every therapeutic line. Unfortunately, the treatment with irinotecan is often associated with severe toxicities, especially neutropenia and diarrhea. The majority of the toxic manifestation is caused by the insufficient deacti...
متن کاملDelayed elimination of SN-38 in cancer patients with severe renal failure.
This prospective study is designed to examine the effects of severe renal failure on the pharmacokinetics of irinotecan. The pharmacokinetics of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), and SN-38 glucuronide (SN-38G) in three cancer patients with severe renal failure [creatinine clearance (Ccr) ≤ 20 ml/min] who were undergoing dialysis and received 100 mg/m(2) irinotecan as monothera...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 25 suppl_4 شماره
صفحات -
تاریخ انتشار 2014